This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

Artificial intelligence companies are largely cheering President Trump’s “AI Action Plan” issued this week — no surprise, ...

C3.ai announced today that CEO Tom Siebel would be stepping down and that the company was in the process of looking for its ...

C3 AI founder and Chief Executive Officer Tom Siebel today announced that he will step down because of health issues.

Shares of artificial intelligence (AI) software company C3.ai (NYSE:AI) fell 10% in the afternoon session after the company ...